The Shark steam mop reviewers say has 'unmatched cleaning power' is $50 off at QVC and selling fast: 'Best floor steamer ever'
Shark is one of the biggest leading brands, bringing shoppers high-tech vacuums, hair tools, fans, and more. We just stumbled across the five-star rated Shark Steam Mop on QVC and the price may shock you.
Shark Steam & Scrub Steam Mop with Steam Blaster Technology
Mop up the savings with this insane Shark deal on QVC!
The top-rated Steam Mop that has shoppers in a frenzy is back and better than ever with a huge 27 percent off.
This tool makes cleaning a breeze and messes a thing of the past with three advanced modes. Shop now with code WELCOME20 to score this price.
$130 (was $180) Shop
Right now the bestselling cleaning tool is majorly marked down to $130 (Yes, you read that right!). If the name Shark did not already speak for itself, this top-rated mop is so multi-functional that your jaw will hit the floor. All it takes is using code WELCOME20 at checkout.
Slim but mighty, this powerhouse Shark Steam Mop tackles messes in minutes, and the best part of all is it takes up barely any space.
The handled find is five star rated, with users calling it the ' best steamer ' they have ever purchased. Weighing only 7.5 lbs, this lightweight device is able to easily be taken on the go or moved between floors of your home.
We know that life gets messy, which is why having a tried and tested cleaning tool at your side is crucial.
The Shark Steam Mop uses three powerful steam modes to perfect your lean, including light, normal, and deep. Each mode tailors to the type of mess from everyday maintenance to year old stains and beyond.
Users of the top-rated steam mop can not believe the versatility, with one saying: 'Best floor steamer ever and I have bought many others. As a professional cleaner, this product in unmatched and takes very little effort to move. High marks!'
Technology is at the heart of the Shark Steam Mop's viral success. The innovative mop uses an advanced Steam Master method that channels powerful, hot steam in a targeted zone to vanish stains and pesky messes seamlessly.
Made for every hard surface floor type, the circular brush head produces 150 scrubs per minute in conjunction with the rave reviewed steam power.
Users attest to the results, with one saying: 'It is a highly effective cleaning tool that combines the power of steam with scrubbing technology to tackle tough dirt and grime on various floor surfaces!'
Unlike many steam mop models, what makes the Shark Steam Mop truly a home run is its chemical free yet effective disinfecting. Shockingly the mop uses just the power of steam to get the deepest clean, leaving out all the negative formulas in the process.
Users find this feature incredible, with one saying: 'Removes stubborn stains and dirt without the need for harsh chemicals. This makes it an excellent choice for households with pets and children, providing a safe and eco-friendly cleaning solution!'
Keeping your home clean is easier said than done, but with the help of Shark, we know you have got this. Try out the Shark Steam Mop, while it is 27 percent off on QVC when you use code WELCOME20 at checkout.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Finextra
7 minutes ago
- Finextra
OpenEden selects BNY as custodian for tokenized T-Bills fund
OpenEden, a leading platform for the tokenization of Real-World Assets ('RWAs'), today announced the appointment of certain affiliates of The Bank of New York Mellon Corporation ('BNY') (NYSE: BK), a global financial services company, as investment manager and primary custodian for the underlying assets of its flagship Tokenized U.S. Treasury Bills ('$TBILL') Fund, the world's first tokenized U.S. Treasury fund to receive an investment grade 'A' rating from Moody's. 0 The strategic relationship highlights OpenEden and BNY's shared commitment to shaping the future of financial infrastructure by facilitating regulated and institutional-grade assets on chain for global investors. Launched in 2023, OpenEden's $TBILL provides investors with direct exposure to a pool of short-dated U.S. Treasury Bills ('U.S. T-Bills') and overnight reverse repurchase agreements through the minting of the TBILL token. $TBILL has seen rapid and accelerating adoption, indicating the surging demand from investors for regulated, institutional-grade on-chain cash management solutions. BNY Investments Dreyfus is one of the largest liquidity managers in the industry with more than five decades of proven expertise and will manage $TBILL Fund on OpenEden's behalf as sub-manager. As part of its mission to build the financial infrastructure for the future, BNY will also serve as the primary custodian for the underlying assets, leveraging its established infrastructure that administers US$55.8 trillion of assets and its proven track record providing asset servicing solutions that enable the digital assets ecosystem. 'OpenEden's collaboration with BNY marks a critical milestone in our mission to deliver secure, transparent, and institution-ready tokenized financial products,' said Jeremy Ng, Founder and CEO of OpenEden. 'Combining our tokenization platform with BNY's global scale and deep fiduciary expertise enables us to create a new standard for trust and access in the digital asset space.' 'BNY plays a critical role in the digital assets ecosystem, serving as a trusted bridge between traditional finance and emerging technology for clients,' said Jose Minaya, Global Head of BNY Investments and Wealth. 'We are excited to extend our time-tested liquidity investment management capabilities and asset safekeeping services to enable $TBILL and are proud to collaborate with OpenEden as we jointly aim to support the end-to-end lifecycle of tokenized assets.'
The Sun
8 minutes ago
- The Sun
Tennis legend Monica Seles, 51, diagnosed with rare muscle-weakening condition as she bravely opens up
TENNIS great Monica Seles revealed she has been diagnosed with a rare muscle-weakening condition. Seles, 51, started experiencing double vision and extremely depleted strength in her arms and legs in 2019. 2 A long string of tests and scans - delayed by the Covid pandemic - ruled out brain tumours and motor neurone disease. The nine-time Grand Slam champion was eventually diagnosed with myasthenia gravis (MG) in 2022. Now Seles has gone public on neuromuscular autoimmune disease - which currently has no cure - and will raise awareness for the condition with an event around this month's US Open. MG affects most of the body but particularly the muscles that control the eyes - although symptoms can vary from day to day. Approximately 15-20 people per 100,000 - or 0.015 per cent of the population - are affected by MG, which sees the immune system attack the neuromuscular junction where nerves and muscles communicate. Seles told AP: "I would be playing [ tennis ] with some kids or family members, and I would miss a ball. "I was like, 'Yeah, I see two balls.' "These are obviously symptoms that you can't ignore. "It took me quite some time to really absorb it, speak openly about it, because it's a difficult one. "It affects my day-to-day life quite a lot." BBC presenter taken to hospital after 'real wake up call' working at Wimbledon and putting off medical care Seles won seven of her nine Grand Slams by the age of 18. That included reaching eight Major finals in a row - winning seven - before she was tragically stabbed in April 1993 on court during a match in Hamburg by a fixated fan of Steffi Graf. The Yugoslavia-born star - who switched nationality to USA - returned in 1995 after a two-year absence. She reached the US Open final in her first Major since the stabbing then won the 1996 Australian Open, her ninth and final Grand Slam title. The lefty, who played with a double-handed forehand and backhand, officialy retired in 2008 five years after her final competitive match. Now living in Florida, she told The Athletic about her MG diagnosis: 'I thought, 'OK, just push through it.' "But a couple of instances happened when — on court and in daily life — I realised there was something going on. What is myasthenia gravis? MYASTHENIA GRAVIS is a rare long-term condition that causes muscle weakness. It typically has phases when it improves and phases when it gets worse. MG usually affects most of the body, spreading from the eyes and face to other areas over weeks, months or years. But for some people with myasthenia gravis, only the eyes are affected. It is common for people to have "flare-ups", where symptoms are very troublesome, followed by periods of remission, where symptoms improve. It's an autoimmune condition, which means it's the result of the immune system (the body's natural defence against infection) mistakenly attacking a healthy part of the body. In myasthenia gravis, the immune system damages the communication system between the nerves and muscles, making the muscles weak and easily tired. It can affect people of any age, typically starting in women under 40 and men over 60. Common symptoms of myasthenia gravis include: droopy eyelids double vision difficulty making facial expressions problems chewing and difficulty swallowing slurred speech weak arms, legs or neck shortness of breath and occasionally serious breathing difficulties The symptoms tend to get worse when you're tired. Many people find they're worse towards the end of the day, and better the next morning after getting some sleep. Source: NHS "After coming out of my former country to the IMG Academy, I had to totally reset. "When I became No1, it was a huge reset because everybody treats you differently. "Then obviously when I got stabbed, that was a huge reset. And then when I was diagnosed, it was a huge reset. "The day-to-day part of managing it, depending on my symptoms, is really adjusting, you know. I think anybody else who has Myasthenia Gravis knows it's a continuous adjustment. "After my stabbing, I had to deal with that internally for quite a few years to process it and my MG diagnosis was kind of very similar. "I had to understand my new normal of day-to-day life, what I can do work-wise and different things."
Reuters
8 minutes ago
- Reuters
Focus: To stay on weight-loss drugs, US patients cut doses and maybe vacations
Aug 13 (Reuters) - Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but as more U.S. insurers restrict coverage people are trimming costs by stretching doses or forgoing expenditures like vacations to pay for the medication out of pocket. A half dozen doctors who spoke with Reuters said insurance coverage has tightened in 2025 as many employers drop it for the expensive GLP-1 drugs. While patients on these medications are counseled on proper diet and exercise, clinical trials show that people who stop taking these drugs are apt to regain weight, opens new tab. Novo Nordisk's ( opens new tab Wegovy and Eli Lilly's (LLY.N), opens new tab Zepbound are weekly injections with U.S. insurer list prices of more than $1,000 a month. For customers willing to pay cash, both drugmakers will ship directly for $499 a month if refills are purchased at fixed intervals. "A significant number of my patients now pay cash," said Dr. Nidhi Kansal, an obesity specialist at Northwestern Medicine in Chicago. "People find a way to scrounge up $6,000 a year, which sucks, because that's a vacation or two." More than a billion people worldwide are obese, according to the U.N. World Health Organization, which has said the GLP-1 drugs could help end the obesity pandemic. A tech industry job change for Yelena Kibasova, a 40-year-old who lives in the Minneapolis area, meant loss of coverage for her Zepbound prescription that helped her achieve and maintain a 150-pound (68-kg) weight loss. "My new company does not cover GLP-1s, so now I am in a kind of purgatory," Kibasova said. "I stopped doing my nails. I stopped doing my hair. Those things are not as important as me staying at a healthy weight." The doctors interviewed by Reuters said patients once leery about long-term obesity treatment are now more comfortable staying on a drug. The doctors said that conversations about temporary use happen only when a patient is trying to lose a certain amount of weight for issues such as fertility treatment or an organ transplant. These obesity specialists said they are hopeful that competition will help bring down prices as new weight-loss options emerge, including new oral drugs that may be available next year. Lilly last week announced trial results for its easier-to-manufacture pill, which was shown to cut patient weight by 12.4%, a few percentage points less than injected drugs. The company hopes to launch it in August 2026. Kenneth Custer, Lilly's head of cardiometabolic health, told Reuters the pill is being tested in several settings, including as a maintenance therapy. Custer declined to comment on how it might be priced. Dr. Anne Peters, an endocrinologist at Keck Medicine USC in Los Angeles, said it is important that patients who reach their weight-loss goal not stop a prescription "cold turkey," so the dose can be tapered down over several months. Peters said about a third of her patients are able to reduce their dose and maintain weight loss, while the rest need to stay on the medication. An analysis of U.S. pharmacy insurance claims found that nearly two-thirds of patients who started on Wegovy or Zepbound in 2024 were still on the medications a year later. Peters said she uses "every technique in the book" to secure insurance coverage for patients, but noted that a growing number of plans no longer pay for the treatments, and patients have to pay out-of-pocket. U.S. pharmacies supply self-injection pens pre-loaded with doses of Wegovy or Zepbound. Lilly's direct-to-consumer service also offers vials. "Some patients can stretch out the vials longer. Get 15 mg, and then give a 10 mg dose for instance," Dr. Peters said, noting that the drug's instructions advise that such an approach should not be taken. Doses of 5 mg, 10 mg and 15 mg are recommended for weight-loss maintenance. Patients also are turning to lower-cost compounded versions of the GLP-1 drugs, or are even mixing them at home with raw ingredients, both of which Peters and other doctors advise against due to safety concerns. Dr. Angela Fitch, former president of the Centennial, Colorado-based Obesity Medicine Association and chief medical officer at online primary care provider Knownwell, said nobody wants to be on a medication, but patients who respond to a GLP-1 drug "really don't want to go off of it when they recognize that it has such a value to them." Both Wegovy and Zepbound were first launched, under the brand names Ozempic and Mounjaro, as diabetes treatments. The class has been linked to a range of benefits, including improved heart health and less sleep apnea. Fitch said the most common reason for her patients to stop taking a GLP-1 drug is loss of insurance coverage. She said her experience is that about 10% of patients are able to reach a target weight and maintain it without further treatment. "We are in a dip where people are dropping coverage," Fitch said, adding that the direct-to-consumer options are an "upper-ish middle-class thing."
